|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results indicate that BRAF(V600E) assessment by pyrosequencing is a reliable assay useful to refine inconclusive cytology of thyroid nodules also in the presence of concurrent HT.
|
23775008 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
In the management of thyroid nodules with benign cytology but positive BRAF(V600E) mutation, thyroidectomy should be considered in nodules which have 2 or more suspicious US features and are considered discordant on image-cytology correlation.
|
25616949 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area.
|
22500044 |
2012 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
To evaluate the role of pre-operative detection of BRAF(V600E) mutation in the FNAB specimens of thyroid nodules in a BRAF(V600E) mutation-prevalent geographical area.
|
17054470 |
2006 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evaluation of the Real-Q BRAF V600E Detection Assay in Fine-Needle Aspiration Samples of Thyroid Nodules.
|
25937618 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation, common in papillary thyroid carcinoma (PTC), is helpful in fine needle aspiration diagnosis of thyroid nodules and is being evaluated for targeted therapies.
|
24746198 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E detection is currently used as molecular test to improve the diagnosis of thyroid nodules, yet it lacks sensitivity.
|
26581891 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation analysis was a useful adjunctive diagnostic tool in the diagnosis of thyroid nodules with suspicious ultrasound features regardless of size.
|
23717622 |
2013 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new gene expression classifier, are outstanding examples that have improved diagnosis of thyroid nodules.
|
23668556 |
2013 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(T1799A) mutation improves the diagnosis of PTC on FNAB, mainly because of the detection of cytopathology false-negatives, and it can be helpful in the routine analysis of thyroid nodules, especially in clinical settings with moderate sensitivity to detect PTC on FNAB.
|
22504197 |
2012 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of BRAF(V600E) in cytology specimens by pyrosequencing is a useful diagnostic adjunctive tool in the evaluation of thyroid nodules also in elderly subjects.
|
24267957 |
2013 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
The application of BRAF(V600E) mutation analysis in US-guided FNAB can improve the diagnostic accuracy of thyroid nodules.
|
21707687 |
2011 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evaluation of BRAF V600E mutation status combined with cytomorphological features for diagnosis of PTC in cytologically indeterminate thyroid nodules can significantly improve diagnostic accuracy and reduce the number of diagnostic operations (calculator available at www.ptc-calc.we2host.lt).
|
29566402 |
2019 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Using pyrosequencing and quantitative methylation-specific PCR (Q-MSP) methods, FNABs from 79 and 38 patients with thyroid nodules in training and test groups, respectively, were analyzed for BRAF(V600E) mutation and gene methylation.
|
24588959 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Seventy-nine of the 504 thyroid nodules had somatic genetic mutations (29 BRAF V600E, 29 NRAS, 8 KRAS, 1 NTRK1, 4 RET/PTC1, and 8 RET/PTC3).
|
21190444 |
2011 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found TERT promoter mutations in 0.0% (0/179) of benign thyroid nodules and 7.0% (9/129) of thyroid nodules of differentiated thyroid cancer, representing a 100% diagnostic specificity and 7.0% sensitivity, with the latter rising to 38.0% (49/129) when combined with BRAF V600E testing.
|
25121551 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
We recommend that patients with a thyroid nodule with any suspicious sonographic feature undergo preoperative BRAF(V600E) testing for risk stratification and to guide the initial surgical approach in PTC.
|
25337709 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
The detection rate of the BRAF(V600E) mutation in thyroid nodules without suspicious US features was only 6.6 % (32/485).
|
24452872 |
2014 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Diagnostic value of BRAF(V600E) mutation analysis of thyroid nodules according to ultrasonographic features and the time of aspiration.
|
20945104 |
2011 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of the study was to determine BRAF T1799A mutation and KRas proto-oncogene mutation, and the analysis of RASSF1A promoter methylation level in cytological material obtained from FNAB specimens of thyroid nodules.
|
26457492 |
2015 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a diagnostic adjunctive tool in the evaluation of thyroid nodules with suspicious cytological findings.
|
17381488 |
2007 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
The preoperative knowledge of the V600E mutation status is fundamental to plan total thyroidectomy with certainty and should be part of the decision tree for the management of thyroid nodules.
|
26854757 |
2016 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
|
22535974 |
2012 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis.
|
31811566 |
2020 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) positivity was a useful marker at thyroid nodules with "suspicious for papillary thyroid carcinoma" or "inadequate" cytological result.
|
19672964 |
2010 |